Q-omics provides the consensus-scored BSG profile across patient tissues and cancer cell-line models. BSG expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, BSG is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, BSG protein abundance shows 20,170 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UCS, and HNSC as cancer lineages where BSG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BSG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BSG survival associations across molecular data types. BSG RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BSG RNA expression–survival associations across cancer types. High BSG expression shows unfavorable associations in UCS, LIHC, LGG, COAD and HNSC, but favorable associations in UCEC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for BSG RNA expression.
This table summarizes BSG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for BSG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BSG shows lower tumor expression in COAD and higher tumor expression in HNSC, KIRP, LIHC, KICH and STAD. The HNSC box plot shows higher BSG RNA expression in tumor versus normal tissue (log2 FC = +0.936, t-test p < 0.001).
This table shows molecular features associated with BSG in patient tissues and cancer cell lines. In patient samples, BSG shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, BSG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
